Inebilizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Inebilizumab and local guidelines before prescribing.
Anti-CD19 antibody
Mechanism
Anti-CD19 monoclonal antibody.
Uses
Neuromyelitis optica spectrum disorder.
Dosing
- Treatment - glucocorticoids (rapid response - e.g. prednisolone 0.6 mg/kg tapering); rituximab for relapse; inebilizumab (anti-CD19) reduces flares; biliary stenting if obstructed.
Clinical Immunology: Autoimmunity, autoantibodies and complement
Side effects
Infusion reactions, infections, hypogammaglobulinaemia.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection
Monitoring
Immunoglobulins
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Screen for hepatitis B and TB.
More from the textbook: uses, cautions and other points
- Newer targeted drugs: inebilizumab (anti-CD19), satralizumab (anti-IL-6 receptor), eculizumab and ravulizumab (complement inhibitors - need meningococcal vaccination).
Neurology: Multiple Sclerosis and inflammatory disease - Inebilizumab / satralizumab / eculizumab | AQP4-positive NMOSD; eculizumab needs meningococcal vaccination.
Neurology: Multiple Sclerosis and inflammatory disease - Long-term prevention (rituximab, inebilizumab, satralizumab or eculizumab).
Neurology: Multiple Sclerosis and inflammatory disease